Anti-hypertensives to Improve Survival Rates in COVID-19 Patients

The COVID-19 pandemic has infected and affected millions of people worldwide. Investigated data shows that severe cases occur in the elderly, those with weakened immune systems, and those who have underlying medical conditions including high blood pressure, diabetes, kidney disease, heart problems, and lung illness, among others. Previously, studies linked hypertension to severe coronavirus disease (COVID-19).

Now, a new study by researchers has found that the risk of severe COVID-19 and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors or Angiotensin Receptor Blockers. Patients with high blood pressure who were regularly taking antihypertensives were 0.67 times less likely to have a fatal or critical outcome than those who were not. The role of these inhibitors, specifically ACEi and ARB, in the pandemic, has not been evaluated.

With cases increasing worldwide, it is vital to understand better the impact of these medicines in hypertensive patients infected with COVID-19.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://people.uea.ac.uk/en/publications/effect-of-reninangiotensinaldosterone-system-inhibitors-in-patients-with-covid19-a-systematic-review-and-metaanalysis-of-28872-patients(c918a250-e796-4d9e-a6e2-6c41fcd04352).html